Prophylaxis against Chagas disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation Profilaxis de enfermedad de Chagas en niños y adultos sometidos a trasplante de órganos sólidos y de precursores hematop
Author
dc.contributor.author
Benítez, Rosana
Author
dc.contributor.author
Noemí, Isabel
Author
dc.contributor.author
Tassara, Renzo
Author
dc.contributor.author
Catalán, Paula
Author
dc.contributor.author
Avilés, Carmen L.
Admission date
dc.date.accessioned
2019-03-15T16:03:29Z
Available date
dc.date.available
2019-03-15T16:03:29Z
Publication date
dc.date.issued
2012
Cita de ítem
dc.identifier.citation
Revista Chilena de Infectologia, Volumen 29, Issue SUPPL.1, 2018, Pages 41-43
Identifier
dc.identifier.issn
07161018
Identifier
dc.identifier.other
10.4067/S0716-10182012000500008
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165844
Abstract
dc.description.abstract
Chagas disease is a zoonosis caused by T. cruzi. The estimated prevalence in endemic areas is 0.6-0.9 / 100,000. In immunocompromised behaves as an opportunistic pathogen highly aggressive and can evolve with meningoencephalitis, myocarditis or systemic disease. We recommend obtaining serology for all donor and recipient of SOT and HSCT. An infected donor should be discarded as such. In the case of D (-) R (+) exists controversy between prophylaxis and pre emptive therapy. The chosen drug for prophylaxis is nifurtimox for 3 months, effective but with relevant adverse effects. Monitoring should be done with RPC and MicroStrout weekly until six months post-transplant, then on a monthly basis for the duration of immunosuppression and continued for life clinical monitoring (C3).
Prophylaxis against Chagas disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation Profilaxis de enfermedad de Chagas en niños y adultos sometidos a trasplante de órganos sólidos y de precursores hematop